NCT05432466View on ClinicalTrials.gov

Clinical Trial to Compare the Efficacy of Celiprolol to Placebo in Patients With Vascular Ehlers-Danlos Syndrome

PHASE3RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

November 7, 2022

Primary Completion Date

March 1, 2029

Study Completion Date

April 1, 2029

Conditions
Vascular Ehlers-Danlos Syndrome
Interventions
DRUG

ACER-002 (celiprolol) 200 mg BID

ACER-002 (celiprolol) 200 mg BID

DRUG

Placebo BID

placebo for ACER-002

Trial Locations (1)

90230

RECRUITING

Science 37, Culver City

Sponsors
All Listed Sponsors
lead

Acer Therapeutics Inc.

INDUSTRY